Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Menter, Alan; Gordon, Kenneth B.; Leonardi, Craig L.; Gu, Yihua; Goldblum, Orin

doi:10.1016/j.jaad.2009.09.040

Cited by 144 publications

(118 citation statements)

References 18 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…In our study, obese patients and patients aged >60 years had significantly lower PASI response rates than their counterparts at some visits. A similar effect of age on response to biological agents in psoriasis was found in a clinical trial of adalimumab [28]. …”

Section: Discussionsupporting

confidence: 61%

Efficacy and Safety of Clinical Use of Etanercept for the Treatment of Moderate-to-Severe Psoriasis in Spain: Results of a Multicentric Prospective Study at 12 Months Follow-Up

Puig

Martínez²,

Carpio³

et al. 2012

Dermatology

View full text Add to dashboard Cite

Background: The efficacy of etanercept in the treatment of psoriasis has been demonstrated in several clinical trials, but information regarding results derived from prospective observational studies in clinical practice is scarce. Objectives: To evaluate the efficacy and safety of etanercept administration according to routine clinical use in moderate-to-severe plaque psoriasis. Materials and Methods: Postauthorization, prospective study, carried out at 59 dermatology units in Spain. Patients diagnosed with moderate-to-severe plaque psoriasis received etanercept during a 12-month period. Results: Altogether, 444 patients were enrolled. Overall, 325 patients (73.2%) initiated etanercept treatment at a dose of 50 mg twice weekly; 96 patients (21.6%) received etanercept as a continuous regimen for the entire study period, and 348 patients (79.4%) an intermittent regimen. Among these, 185 patients (41.6% overall) received one course of treatment, stopped at various study points and did not restart etanercept treatment, whereas the remaining 163 patients (36.7% overall) stopped etanercept treatment, lost response, relapsed and were retreated. Most patients who interrupted etanercept treatment did so at month 6. Altogether, 79.7% of patients completed the study period. Etanercept treatment resulted in significant improvement in disease activity. A Psoriasis Area and Severity Index (PASI) 75 response was achieved by 76.1% of patients at month 6. Out of 252 adverse events reported, 31 were considered severe. Three possibly treatment-related malignancies were detected during the study. No opportunistic infections, tuberculosis or demyelinating events were reported. Conclusion: The PASI 75 response rate at month 6 in this observational, naturalistic study is similar to those observed in recent published trials with etanercept, and within the range of those reported for other marketed biologicals.

show abstract

Section: Discussionsupporting

confidence: 61%

Efficacy and Safety of Clinical Use of Etanercept for the Treatment of Moderate-to-Severe Psoriasis in Spain: Results of a Multicentric Prospective Study at 12 Months Follow-Up

Puig

Martínez²,

Carpio³

et al. 2012

Dermatology

View full text Add to dashboard Cite

show abstract

“…9,10 In this study, etanercept was effective for patients with BMI greater than 35 kg/m 2 . Because the high-BMI subgroups were small (Group A, n = 18; Group B, n = 16), these results should be interpreted with caution.…”

Section: Discussionmentioning

confidence: 67%

Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept

Bagel

Lynde

Tyring

et al. 2012

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…17 Although the standard approved dosing regimens of these biologic agents have been established in large, randomized, double-blind, placebo-controlled clinical trials, clinical experience in real-world practice settings suggests that off-label dosing regimens are frequently used and clinically relevant. [18][19][20][21][22][23][24][25][26] Off-label dosing regimens can be broadly categorized as dose escalations, dose reductions, intermittent therapy, or interruptions in therapy followed by retreatment. 18 The reasons for these dose adjustments may be to improve efficacy in very…”

mentioning

confidence: 99%

Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis

Feldman¹,

Zhao²,

Navaratnam³

et al. 2015

JMCP

View full text Add to dashboard Cite

show abstract

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Cited by 144 publications

References 18 publications

Efficacy and Safety of Clinical Use of Etanercept for the Treatment of Moderate-to-Severe Psoriasis in Spain: Results of a Multicentric Prospective Study at 12 Months Follow-Up

Efficacy and Safety of Clinical Use of Etanercept for the Treatment of Moderate-to-Severe Psoriasis in Spain: Results of a Multicentric Prospective Study at 12 Months Follow-Up

Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept

Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis

Contact Info

Product

Resources

About